Navigation Links
Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS
Date:10/11/2007

arkedly reduced in alemtuzumab-treated patients compared to Rebif-treated patients. Data from CAMMS223 provide the rationale for the newly initiated Phase 3 CARE-MS I clinical trial in untreated patients with relapsing-remitting multiple sclerosis.

-- Two-year Results with Alemtuzumab in Patients with Active Relapsing-

Remitting Multiple Sclerosis Who Have Failed Licensed Beta-Interferon

Therapies.

Saturday, October 13 from 3:30-5:00 p.m. Ed Fox, M.D.

In another poster presentation, data from an investigator-sponsored study demonstrate the benefits of alemtuzumab in previously treated MS patients. Data from this two-year study evaluate the effect of two annual cycles of alemtuzumab on patients with relapsing-remitting MS who had failed prior treatment with licensed beta-interferons. Reported at ECTRIMS will be new data on patient functioning as measured by the Multiple Sclerosis Functional Composite Scale cited above. Data from this study provides the basis for the second Phase 3 clinical trial, CARE-MS II, in patients who have continued to relapse while using a licensed therapy. This study is also open to enrollment.

Genzyme and Bayer Schering Pharma AG, Germany are co-developing alemtuzumab in oncology, multiple sclerosis and other indications. Bayer Schering Pharma AG, Germany holds exclusive worldwide marketing and distribution rights to alemtuzumab.

Alemtuzumab is an investigational drug for the treatment of MS and must not be used in MS patients outside of a formal clinical trial setting. Physicians or patients seeking additional information about the CARE-MS trials should contact Genzyme Medical Information at 1-800-745-4447, option 2 in the United States, + 31 35 6991499 in Europe, or visit http://www.clinicaltrials.gov.

About Multiple Sclerosis

Multiple Sclerosis (MS) is a chronic disease of the central nervous system (CNS) in which the
'/>"/>

SOURCE Genzyme
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Genzyme Announces First Phase III Study of Tolevamer in Diarrhea Patients
2. Bayer Voluntarily Withdraws BAYCOL - A Drug Associated With 50 Deaths
3. Bayer Wins Positive Response For Marketing Its Cancer Drug
4. Genomatix Licensed By Bayer Healthcare
5. Bayer to Market Biocon Insulin in China
6. Test for Esophageal Reflux Licensed to Bayer by University
7. Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer
8. Dow Acquires Wolff Walsrode from Bayer
9. Asmanex Twisthaler launched by Schering-Plough for treatment of asthma
10. India to benefit from pharma companies move
11. South Africa Wins landmark case against pharmaceutical giants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... (PRWEB) July 13, 2014 Hope Palliative & ... monthly grief support group at the Tamarack Senior Living Community ... held at 10:30 A.M. on the 3rd Wednesdays of every ... 2014 at the Tamarack Community located at 55 S. Greeley ... bereaved individuals and there is no cost for the group. ...
(Date:7/12/2014)... July 13, 2014 According to the ... (Land Systems, Airborne Systems, and Naval Systems) - Global ... MarketsandMarkets, Security and Surveillance Radar market are estimated to ... register a CAGR of 5.97% to reach $8.61 billion ... tables with 47 figures spread through 161 pages and ...
(Date:7/12/2014)... Fresh off their respective performances in the 2014 World ... 5th at Sun Life Stadium in an international friendly. The ... brightest stars in the world of football in Colombian and ... to some of the best talent in the world in ... best team in the world according to the Fédération Internationale ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 ... research report, ‘cognitive assessment and training’ is ... monitor, assess, train, or enhance cognitive functions. ... such as in dementia screening, clinical trials, ... classroom learning, self assessment, brain training, and ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Casinos ... years, despite rising competition from international and online casinos. ... 2.9% over the five years through 2014-15. Greater per ... demanding more gaming services. Rises in discretionary income levels ... more money on non-essential items such as casino gambling ...
Breaking Medicine News(10 mins):Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 2Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 4
... All," Interaction Associates Senior Consultant Jay Gordon Cone provides a model ... teams are high-performing - and decide what to do if they,re ... ... of the work of business today takes place in team environments. ...
... Journal of Hematology by scientists from the Fudan-Cinpathogen ... Shanghai, in collaboration with the University of ... subtypes of chronic lymphoid neoplasms are not as ... Diagnosis and classification were performed by a single ...
... with current US treatment guidelines to start ... 80% of patients may need multiple medications to help them reach ... blood pressure goals, - Single-pill ... could help patients reach treatment goals faster, - Diovan HCT and ...
... or at the neighborhood pool, diving is one of the ... of people do it* and every four years during the ... you that researchers are just now delving into the dangers ... competing at the highest levels of diving takes persistence. Day ...
... children and a highly touted botanical extract (COLD-fX) show ... Canadian cold and flu remedy. The results appear in ... the official journal of the American Academy of Pediatrics. ... was conducted in collaboration with the University of Alberta ...
... Today, the University,HealthSystem Consortium (UHC) announced that ... medical center (AMC) in Jackson, has,been added to ... chain,participants., "Moving to UHC for our group ... strategic partner that is committed to meeting our,unique ...
Cached Medicine News:Health News:New White Paper by Performance Improvement Innovator Interaction Associates Helps Business Leaders Assess Team Effectiveness 2Health News:Fudan-Cinpathogen Study Shows Chronic Lymphoid Neoplasms are More Common in Shanghai Than Thought 2Health News:Single-Pill Combinations Diovan HCT and Exforge Approved in US as First-Line Treatments for High Blood Pressure 2Health News:Single-Pill Combinations Diovan HCT and Exforge Approved in US as First-Line Treatments for High Blood Pressure 3Health News:Single-Pill Combinations Diovan HCT and Exforge Approved in US as First-Line Treatments for High Blood Pressure 4Health News:Single-Pill Combinations Diovan HCT and Exforge Approved in US as First-Line Treatments for High Blood Pressure 5Health News:Single-Pill Combinations Diovan HCT and Exforge Approved in US as First-Line Treatments for High Blood Pressure 6Health News:Single-Pill Combinations Diovan HCT and Exforge Approved in US as First-Line Treatments for High Blood Pressure 7Health News:First national study of diving-related injuries 2Health News:First national study of diving-related injuries 3Health News:Canadian study of colds and kids: Positive safety results for ginseng extract 2Health News:University of Mississippi Health Care Selects UHC for Group Purchasing Services 2
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
(Date:7/10/2014)... , July 10, 2014  Decision Resources Group ... infectious disease (ID) specialists are willing to prescribe ... (oritavancin) for use as OPAT, approximately two-thirds of ... agents to their hospital inpatients. However, our findings ... patients are initiated on OPAT following hospital discharge, ...
(Date:7/10/2014)... , July 10, 2014 CVS Caremark Corporation (NYSE: ... directors has approved a quarterly dividend of $0.275 (27.5 cents) ... payable on August 1, 2014, to holders of record on ... CVS Caremark is dedicated to helping people on their ... in the United States . Through the ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... Employment Awareness Month marks the 20th anniversary ... the cutting-edge voice of disability culture in America. ... and edited by staff and freelancers with disabilities, encourages ... while simultaneously reflecting the vibrant world of disability-related arts, ...
... PHILADELPHIA, Oct. 21 Sanovia, a leading provider ... it has been selected by HealthSpring, Inc. to ... HealthSpring, one of the largest Medicare Advantage coordinated ... reinforces Sanovia,s leadership in delivering pharmaceutical prior authorization ...
Cached Medicine Technology:Award-Winning Disability Lifestyle Magazine Celebrates 20 Years of Publication - And 20 Years of Employing People with Disabilities 2Sanovia Selected to Deliver PA-Logic(TM) Pharmaceutical Prior Authorization Platform to HealthSpring 2Sanovia Selected to Deliver PA-Logic(TM) Pharmaceutical Prior Authorization Platform to HealthSpring 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: